Get started
Author

Yuuichi Sakurai

Observed name: Sakurai, Yuuichi
Institution: Takeda (Japan)
OpenAlex ID: A5113904302
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study
2016 · Kazunari Murakami, Yuuichi Sakurai, et al. · Gut · 465
PDF
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects
2015 · Yuuichi Sakurai, Akira Nishimura, et al. · Clinical and Translational Gastroenterology · 189
Potassium-competitive acid blockers: Advanced therapeutic option for acid-related diseases
2016 · Nobuhiro Inatomi, Jun Matsukawa, et al. · Pharmacology & Therapeutics · 166
PDF
Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole
2018 · Kiyoshi Ashida, Katsuhiko Iwakiri, et al. · World Journal of Gastroenterology · 111
PDF
Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438)
2016 · Kazuyoshi Otake, Yuuichi Sakurai, et al. · Advances in Therapy · 103
Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
2016 · Yoshikazu Kinoshita, Yuuichi Sakurai, et al. · Current Therapeutic Research · 68
PDF
A randomized, double-blind study to evaluate the acid-inhibitory effect of vonoprazan (20 mg and 40 mg) in patients with proton-pump inhibitor-resistant erosive esophagitis
2017 · Katsuhiko Iwakiri, Yuuichi Sakurai, et al. · Therapeutic Advances in Gastroenterology · 64
PDF
Efficacy and Safety of Vonoprazan in Patients With Nonerosive Gastroesophageal Reflux Disease: A Randomized, Placebo-Controlled, Phase 3 Study
2019 · Yoshikazu Kinoshita, Yuuichi Sakurai, et al. · Clinical and Translational Gastroenterology · 52
Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study
2016 · Yuuichi Sakurai, Madoka Shiino, et al. · Advances in Therapy · 43
Pharmacokinetic Drug–Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese Men
2016 · Yuuichi Sakurai, Madoka Shiino, et al. · Clinical Drug Investigation · 20
PDF
Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial
2024 · Yinglian Xiao, Jiaming Qian, et al. · Chinese Medical Journal · 17
Tu1056 A Phase 3, Double-Blind Study of a Triple Therapy With TAK-438, Amoxicillin, and Clarithromycin As First Line Eradication of H. pylori and a Triple Therapy With TAK-438, Amoxicillin, and Metronidazole As Second Line Eradication of H. pylori
2014 · Kazunari Murakami, Yuuichi Sakurai, et al. · Gastroenterology · 13
Tu1052 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (10 mg or 20 mg Once-Daily) Compared to Lansoprazole (15 mg Once-Daily) in a 24-Week Maintenance Treatment for Healed Erosive Esophagitis
2014 · Eiji Umegaki, Katsuhiko Iwakiri, et al. · Gastroenterology · 9
Tu1059 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of TAK-438 (20 mg Once-Daily) Compared to Lansoprazole (30 mg Once-Daily) in Patients With Erosive Esophagitis
2014 · Katsuhiko Iwakiri, Eiji Umegaki, et al. · Gastroenterology · 8
PDF
Mo1053 A Phase 2, Randomized, Double-Blind, Parallel-Group, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety of a Novel Potassium-Competitive Acid Blocker (P-CAB) TAK-438 in Patients With Erosive Esophagitis
2013 · Tsutomu Chiba, Yuuichi Sakurai, et al. · Gastroenterology · 3
PDF
Tu1321 VONOPRAZAN 10 OR 20 MG DEMONSTRATED SUPERIORITY OVER LANZOPRAZOLE 15 MG IN PREVENTING RELAPSE IN ASIAN PATIENTS WITH ENDOSCOPIC HEALING OF EROSIVE ESOPHAGITIS: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, MULTICENTER STUDY
2020 · Yinglian Xiao, Jiaming Qian, et al. · Gastroenterology · 2
Reply to the letter by Dr Graham concerning ethical and interpretation issues with vonoprazan-containing H. pylori eradication therapy
2016 · Kazunari Murakami, Yuuichi Sakurai, et al. · Gut · 1
Su1119 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Dose-Response Relationships of Acid-Inhibitory Effect of Vonoprazan (20 mg, 40 mg) in Patients With Proton Pump Inhibitor-Resistant Erosive Esophagitis
2016 · Katsuhiko Iwakiri, Eiji Umegaki, et al. · Gastroenterology · 1
Mo1147 A Crossover Study to Evaluate the Acid-Inhibitory Effect of a Newly Developed Potassium-Competitive Acid Blocker, Vonoprazan, Compared With Esomeprazole or Rabeprazole
2015 · Yuuichi Sakurai, Yuuya Mori, et al. · Gastroenterology · 1
PDF
Works count: 21
Citation count: 1,336
H-index: 12
I10-index: 12
Year
Topic
Type